These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32890789)

  • 21. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ
    Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis.
    He Y; Zhang J; Shen G; Liu L; Zhao Q; Lu X; Yang H; Hong D
    BMC Pharmacol Toxicol; 2019 Oct; 20(1):62. PubMed ID: 31665091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
    Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
    Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
    Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Reinhorn D; Yerushalmi R; Moore A; Desnoyers A; Saleh RR; Amir E; Goldvaser H
    Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
    Yu Q; Xu Y; Yu E; Zheng Z
    J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
    Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
    J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Le B; Richard L; Shariff SZ; Ouédraogo AM; Pritchard KI; Raphael J; Vandenberg T; Fernandes R; Desautels DN; Chan KKW; Earle CC
    Breast; 2021 Dec; 60():295-301. PubMed ID: 34728119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
    He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
    J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
    Hamood R; Hamood H; Merhasin I; Keinan-Boker L
    Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Xu X; Chlebowski RT; Shi J; Barac A; Haque R
    Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
    Ligibel JA; James O'Malley A; Fisher M; Daniel GW; Winer EP; Keating NL
    Breast Cancer Res Treat; 2012 Jan; 131(2):589-97. PubMed ID: 21881937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Le B; Richard L; Shariff SZ; Pritchard KI; Raphael J; Vandenberg T; Fernandes R; Desautels D; Chan KKW; Earle CC
    J Geriatr Oncol; 2020 Sep; 11(7):1132-1137. PubMed ID: 32611495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of aromatase inhibitor therapy in breast cancer.
    Lintermans A; Neven P
    Expert Opin Drug Saf; 2015 Aug; 14(8):1201-11. PubMed ID: 26059833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.